BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Nears Dosing of Phase 2 Patients with Standout Anthracycline Therapy
CNS Pharmaceuticals (NASDAQ: CNSP) is focused on producing a treatment that improves on the effectiveness of established chemotherapy drug lomustine in increasing overall survival rates of glioblastoma multiforme (“GBM”) patients. GBM is an illness that is nearly 100% fatal in patients just over a year after diagnosis. CNS Pharmaceuticals’ lead drug candidate, Berubicin, has been granted investigational new drug (“IND”) status after promising findings. “Berubicin is a standout anthracycline therapy because of its novel apparent ability to cross the blood-brain barrier to combat neurological tumors. The drug was the subject of a Phase I trial some 15 years ago in…